Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model

Nature Medicine

Volumn 11, Issue 1, 2005, Pages 43-49

  Sano, Shigetoshi ^a,c   Chan, Keith Syson ^a   Carbajal, Steve ^a   Clifford, John ^b   Peavey, Mary ^a   Kiguchi, Kaoru ^a   Itami, Satoshi ^c   Nickoloff, Brian J ^d   DiGiovanni, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; STAT3C PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; KERATINOCYTE; MALE; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EPIDERMIS; HUMANS; KERATINOCYTES; MICE; MICE, TRANSGENIC; PSORIASIS; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANS-ACTIVATORS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS MUSCULUS;

EID: 13444269249     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1162     Document Type: Article

References (46)

1. Gottlieb, A., and Bos, J. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol. 105, 105-116 (2002).
2. Valdimarsson, H., Baker, B.S., Jonsdottir, I., Powles, A. & Fry, L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today 16, 145-149 (1995).
3. Christophers, E. The immunopathology of psoriasis. Int. Arch. Allergy Immunol. 110, 199-206 (1996).
4. Bos, J.D. & De Rie, M.A. The pathogenesis of psoriasis: immunological facts and speculations. Immunol. Today 20, 40-46 (1999).
5. Koo, J., Nguyen, Q. & Gambia, C. Advances in psoriasis therapy. Adv. Dermatol. 12, 47-72 (1997).
6. Eedy, D.J., Burrows, D., Bridges, J.M. & Jones, F.G. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 300, 908 (1990).
7. Gardembas-Pain, M. et al. Psoriasis after allogeneic bone marrow transplantation. Arch. Dermatol. 126, 1523 (1990).
8. Lewis, H.M. et al. Restricted T-cell receptor V beta gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br. J. Dermatol. 129, 514-520 (1993).
9. Leung, D.Y. et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 96, 2106-2112 (1995).
10. Wrone-Smith, T. & Nickoloff, B.J. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98, 1878-1887 (1996).
11. + T cells induces psoriasis. Am. J. Pathol. 155, 145-58 (1999),
12. Gilhar, A., David, M., Ullmann, Y., Berkutski, T. & Kalish, R.S. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J. Invest. Dermatol. 109, 283-288 (1997).
13. Schon, M.P. Animal models of psoriasis - what can we learn from them? J. Invest. Dermatol. 112, 405-410 (1999).
14. Li, A.G., Wang, D., Feng, X.H. & Wang, X.J. Latent TGFβ1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. 23, 1770-1781 (2004).
15. Cook P.W. et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 100, 2286-2294 (1997).
16. Xia, Y.P. et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102, 161-168 (2003).
17. Blumberg, H. et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104, 9-19 (2001).
18. Leonard, W.J. & O'Shea, J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293-322 (1998).
19. Levy, D.E. & Darnell, J.E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (9), 651-662 (2002).
20. Hirano, T., Ishihara, K. & Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2456 (2000).
21. Turkson, J. & Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626 (2000).
22. Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18, 4657-4668 (1999).
23. Sano, S., Takeda, J., Yoshikawa, K. & Itami, S. Tissue regeneration: hair follicle as a model. J. Investig. Dermatol. Symp. Proc. 6, 43-48 (2001).
24. Takeda, J., Sano, S., Tarutani, M., Umeda, J. & Kondoh, G. Conditional gene targeting and its application in the skin. J. Dermatol. Sci. 23, 147-54 (2000).
25. Hertle, M.D., Kubler, M.D., Leigh, I.M. & Watt, F.M. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J. Clin. Invest. 89, 1892-1901 (1992).
26. Drtonne, J.P. Aetiology and pathogenesis of psoriasis. Br. J. Dermatol. 135 Suppl 49, 1-5 (1996).
27. Piepkorn, M., Pittelkow, M.R. & Cook, P.W. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J. Invest. Dermatol. 111, 715-721 (1998).
28. Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295-303 (1999).
29. Murillas, R. et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14, 5216-5223 (1995).
30. Chan, K.S. et al. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 64, 2382-2389 (2004).
31. Chan, K.S. et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114, 720-728 (2004).
32. Thewes, M., Stadler, R., Korge, B. & Mischke, D. Normal psoriatic epidermis expression of hyperproliferation-associated keratins. Arch. Dermatol. Res. 283, 465-471 (1991).
33. Ghadially, R., Reed, J.T. & Elias, P.M. Stratum corneum structure and function correlates with phenotype in psoriasis. J. Invest. Dermatol. 107, 558-564 (1996).
34. Miller, R.A. The Koebner phenomenon. Int. J. Dermatol. 21, 192-197 (1982).
35. Detmar, M. et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 180, 1141-1146 (1994).
36. Leong, P.L. et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 100, 4138-4143 (2003).
37. McKenzie, R.C. & Sabin, E. Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp. Dermatol. 12, 337-345 (2003).
38. Griffiths, C.E., Voorhees, J.J. & Nickoloff, B.J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J. Am. Acad. Dermatol. 20, 617-629 (1989).
39. Caldenhoven, E. et al. Activation of the STAT3/acute phase response factor transcription factor by interleukin-5. J. Biol. Chem. 270, 25778-25784 (1995).
40. Lebwohl, M. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004-2013 (2003).
41. Krueger, J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1-23 (2002).
42. Lew, W. et al. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol. 25, 295-305 (2004).
43. Baker, B.S., Powles, A. V., Valdimarsson, H., & Fry, L. An altered response by psoriatic keratinocytes to gamma interferon. Scand J. Immunol. 28, 735-740 (1988).
44. Nickoloff, B. J., Mitra, R. S., Elder, J. T., Fisher, G. J., & Voorhees, J. J. Decreased growth inhibition by recombinant γ interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br. J. Dermatol. 121, 161-174 (1989).
45. Sato, T., Selleri, C., Young, N.S., & Maciejewski, J.P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-γ due to phosphorylation of Stat1 and Stat3. Blood 90, 4749-4758 (1997).
46. Qing, Y. & Stark, G.R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279, 41679-41685 (2004).